X4 Pharmaceuticals Q2 FY26 net loss narrows to $16.2 million; revenue rises to $8.81 million

Reuters2026/08/06 21:47

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

X4 Pharmaceuticals posted Q2 2026 revenue of USD 8.81 million, swinging from USD 1.97 million a year earlier.
Net loss narrowed to USD 16.16 million, or USD 0.13 per share, from a loss of USD 25.74 million, or USD 3.47 per share.
R&D expense fell to USD 15.08 million from USD 18.35 million, due to lower headcount, partly offset by higher 4WARD CRO costs.
Cash position totaled USD 208 million at June 30, with management pointing to a cash runway into 2029.
Operationally, it shifted the Phase 3 4WARD trial to a new CRO, expects an FDA sample-size update, and cited EU authorization of XOLREMDI for WHIM syndrome.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

X4 Pharmaceuticals Q2 FY26 net loss narrows to $16.2 million; revenue rises to $8.81 million

You may also like

Crypto prices